Key facts
- It has raised $135.0M across 7 recorded rounds; the latest was Later Stage VC (Series C) ($135.0M) in Jul 2021.
- 4 institutional filers report fund marks on Amylyx Pharmaceuticals across 35 filings.
- Amylyx Pharmaceuticals has filed 10 Form Ds with the SEC since 2015, most recently Jul 2020 ($30.0M sold to 17 investors).
Free account
See the evidence behind this price
- ·Post-money valuations for all 7 rounds
- ·Watchlist + deal alerts for Amylyx Pharmaceuticals
Create free account
No card required
Funding rounds
7 roundsJul 2021Later Stage VC (Series C)$135.0M▮
About Amylyx Pharmaceuticals
- Industry
- Drug Discovery
PA Mark — not yet priced
Amylyx Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Pro members can request priority coverage with a 48-hour turnaround.
Recorded secondary trades
No prints on record
No secondary trades in Amylyx Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
4 filers · latest Jun 20264 SEC-registered funds reported 35 fair-value marks on Amylyx Pharmaceuticals between May 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.